Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address: adezern1@jhmi.edu.

Comment

Maximilian Stahl et al. Lancet Haematol. 2024 Jan.

. 2024 Jan;11(1):e5-e7.

doi: 10.1016/S2352-3026(23)00343-5. Epub 2023 Dec 5.

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. Electronic address: adezern1@jhmi.edu.

No abstract available

Conflict of interest statement

We declare no competing interests.

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Zeidan AM, et al. Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5. Lancet Haematol. 2024. PMID: 38065203 Clinical Trial.